ES2510565T3 - Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno - Google Patents

Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno Download PDF

Info

Publication number
ES2510565T3
ES2510565T3 ES08801986.4T ES08801986T ES2510565T3 ES 2510565 T3 ES2510565 T3 ES 2510565T3 ES 08801986 T ES08801986 T ES 08801986T ES 2510565 T3 ES2510565 T3 ES 2510565T3
Authority
ES
Spain
Prior art keywords
neramexane
treatment
dose adjustment
internal ear
ear disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08801986.4T
Other languages
English (en)
Inventor
Barbara Ellers-Lenz
Tanja Rosenberg
Erhard Seiller
Hagen Krueger
Michael Althaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Application granted granted Critical
Publication of ES2510565T3 publication Critical patent/ES2510565T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

Neramexano o una sal farmacéuticamente aceptable del mismo para su uso en el tratamiento de un trastorno del oído interno, donde dicho neramexano o sal farmacéuticamente aceptable del mismo se administra en un esquema de ajuste de dosis que comprende un ajuste ascendente de la dosis del neramexano o de una sal farmacéuticamente aceptable del mismo en dosis crecientes por etapas de 25 mg o 12,5 mg a intervalos semanales durante un periodo de cuatro a cinco semanas para conseguir una dosis eficaz de 50 a 75 mg al día.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26

Claims (1)

  1. imagen1
    imagen2
ES08801986.4T 2007-09-12 2008-09-10 Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno Active ES2510565T3 (es)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US99339607P 2007-09-12 2007-09-12
EP07253630 2007-09-12
US993396P 2007-09-12
EP07253630 2007-09-12
US6702608P 2008-02-25 2008-02-25
US6708308P 2008-02-25 2008-02-25
US6693108P 2008-02-25 2008-02-25
US67026P 2008-02-25
US66931P 2008-02-25
US67083P 2008-02-25
EP08004777 2008-03-14
EP08004778 2008-03-14
EP08004776 2008-03-14
EP08004776 2008-03-14
EP08004778 2008-03-14
EP08004777 2008-03-14
PCT/EP2008/007420 WO2009033651A1 (en) 2007-09-12 2008-09-10 Titration package for neramexane and its use in the treatment of an inner ear disorder

Publications (1)

Publication Number Publication Date
ES2510565T3 true ES2510565T3 (es) 2014-10-21

Family

ID=40451596

Family Applications (5)

Application Number Title Priority Date Filing Date
ES08801986.4T Active ES2510565T3 (es) 2007-09-12 2008-09-10 Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno
ES11005567.0T Active ES2596262T3 (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para su uso en el tratamiento de tinnitus asociado con pérdida de audición
ES08801985.6T Active ES2604945T3 (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para el tratamiento y prevención de pérdida de audición
ES12006826.7T Active ES2562709T3 (es) 2007-09-12 2008-09-10 Envase de ajuste de dosis para 1-amino-alquilciclohexanos
ES08801987T Active ES2377253T3 (es) 2007-09-12 2008-09-10 Neramexano para uso en el tratamiento de tinitus subagudo

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES11005567.0T Active ES2596262T3 (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para su uso en el tratamiento de tinnitus asociado con pérdida de audición
ES08801985.6T Active ES2604945T3 (es) 2007-09-12 2008-09-10 Derivados de 1-amino-alquilciclohexano para el tratamiento y prevención de pérdida de audición
ES12006826.7T Active ES2562709T3 (es) 2007-09-12 2008-09-10 Envase de ajuste de dosis para 1-amino-alquilciclohexanos
ES08801987T Active ES2377253T3 (es) 2007-09-12 2008-09-10 Neramexano para uso en el tratamiento de tinitus subagudo

Country Status (21)

Country Link
US (6) US20110086916A1 (es)
EP (6) EP2200598A1 (es)
JP (6) JP5613053B2 (es)
KR (4) KR20100052556A (es)
CN (4) CN101801366A (es)
AR (3) AR071728A1 (es)
AT (1) ATE532507T1 (es)
AU (4) AU2008298017B2 (es)
BR (2) BRPI0816690A2 (es)
CA (4) CA2699209A1 (es)
DK (1) DK2200600T3 (es)
ES (5) ES2510565T3 (es)
HR (1) HRP20120046T1 (es)
MX (4) MX2010002733A (es)
PL (1) PL2200600T3 (es)
PT (1) PT2200600E (es)
RU (1) RU2011137131A (es)
SI (1) SI2200600T1 (es)
TW (3) TW200918042A (es)
WO (4) WO2009033650A1 (es)
ZA (4) ZA201001262B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2200600T3 (pl) * 2007-09-12 2012-04-30 Merz Pharma Gmbh & Co Kgaa Nerameksan do zastosowania w leczeniu podostrego szumu usznego
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2011160839A1 (en) 2010-06-24 2011-12-29 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
US20130296427A1 (en) * 2011-01-20 2013-11-07 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
CA2904055A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
CN106535883A (zh) * 2014-04-28 2017-03-22 杏林制药株式会社 耳鸣患者的治疗用药剂
EP3138559A4 (en) * 2014-04-28 2017-10-25 Kyorin Pharmaceutical Co., Ltd. Drug for treatment of tinnitus patients
CA2999467C (en) 2014-10-23 2023-10-10 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor
PL3297628T3 (pl) * 2015-05-18 2021-12-06 Sensorion Azasetron do stosowania w leczeniu niedosłuchu
KR101893604B1 (ko) 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
CN105924362B (zh) * 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
KR102268893B1 (ko) 2020-01-16 2021-06-24 경북대학교 산학협력단 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물
CN111477199B (zh) * 2020-04-02 2021-11-30 北京瑞迪欧文化传播有限责任公司 一种嵌入式音乐控制系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
CA2172509C (en) 1993-10-22 2010-08-24 Jeffrey L. Cleland Methods and compositions for microencapsulation of antigens for use as vaccines
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
AU4424697A (en) * 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
EP1009732B1 (en) * 1997-06-30 2003-05-21 MERZ + CO. GmbH & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
JP2003531187A (ja) * 2000-04-26 2003-10-21 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択的ｎｍｄａ受容体アンタゴニストとしてのシクロヘキシルアミン誘導体
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
JP2004021734A (ja) 2002-06-18 2004-01-22 Nokia Corp キーパッドおよびキーパッドシステム
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
EP1545551A4 (en) * 2002-09-06 2008-10-22 Durect Corp DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
EA010430B1 (ru) * 2003-05-27 2008-08-29 Форест Лэборэтериз, Инк. Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR20090033410A (ko) 2004-06-17 2009-04-02 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20060264897A1 (en) * 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2006096518A2 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Improved gacyclidine formulations
TWI265036B (en) * 2005-04-29 2006-11-01 Guo-Ming Huang Safety injector and method of operating the same
US8062205B2 (en) * 2005-05-18 2011-11-22 Gt Urological, Llc Drug elution for implantable incontinence devices
CN1896729A (zh) 2005-07-15 2007-01-17 复旦大学附属中山医院 纳米药物自组装双稳态量子线阵列及其制备方法
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
PL2200600T3 (pl) * 2007-09-12 2012-04-30 Merz Pharma Gmbh & Co Kgaa Nerameksan do zastosowania w leczeniu podostrego szumu usznego
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
AU2009291244A1 (en) * 2008-09-10 2010-03-18 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US20130296427A1 (en) * 2011-01-20 2013-11-07 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss

Also Published As

Publication number Publication date
CN101835469A (zh) 2010-09-15
CN101801366A (zh) 2010-08-11
JP5563461B2 (ja) 2014-07-30
US20110077304A1 (en) 2011-03-31
BRPI0816690A2 (pt) 2016-11-01
KR20100052559A (ko) 2010-05-19
CA2699209A1 (en) 2009-03-19
KR20100052557A (ko) 2010-05-19
CA2699207A1 (en) 2009-03-19
AU2008298017B2 (en) 2012-03-01
JP5784189B2 (ja) 2015-09-24
TW200922544A (en) 2009-06-01
CN101801365A (zh) 2010-08-11
TW200927087A (en) 2009-07-01
AU2008298017A1 (en) 2009-03-19
US20100298441A1 (en) 2010-11-25
US20170027885A1 (en) 2017-02-02
ES2596262T3 (es) 2017-01-05
US20110086916A1 (en) 2011-04-14
HRP20120046T1 (hr) 2012-02-29
EP2200599A1 (en) 2010-06-30
AR071728A1 (es) 2010-07-14
AU2008298016B2 (en) 2012-02-02
CN101795679A (zh) 2010-08-04
WO2009033650A1 (en) 2009-03-19
ZA201001262B (en) 2011-07-27
MX2010002735A (es) 2010-04-01
AU2008298016A1 (en) 2009-03-19
EP2200599B1 (en) 2016-08-31
AR070025A1 (es) 2010-03-10
EP2386299A2 (en) 2011-11-16
ES2377253T3 (es) 2012-03-23
BRPI0816712A2 (pt) 2016-11-08
EP2386299A3 (en) 2012-05-02
JP5613053B2 (ja) 2014-10-22
EP2203163A1 (en) 2010-07-07
AU2008298018A1 (en) 2009-03-19
KR20100052556A (ko) 2010-05-19
MX2010002736A (es) 2010-04-01
DK2200600T3 (da) 2012-01-23
JP2010539116A (ja) 2010-12-16
CA2699210A1 (en) 2009-03-19
AU2008298015B2 (en) 2012-03-22
EP2203163B1 (en) 2014-08-27
JP5563460B2 (ja) 2014-07-30
US20150018425A1 (en) 2015-01-15
US20100298440A1 (en) 2010-11-25
MX2010002733A (es) 2010-04-09
MX2010002734A (es) 2010-04-01
EP2386299B1 (en) 2016-07-13
JP2010539115A (ja) 2010-12-16
PL2200600T3 (pl) 2012-04-30
AU2008298018B2 (en) 2012-01-19
EP2548552A3 (en) 2013-10-16
SI2200600T1 (sl) 2012-03-30
EP2200598A1 (en) 2010-06-30
JP5784188B2 (ja) 2015-09-24
WO2009033651A1 (en) 2009-03-19
EP2200600A1 (en) 2010-06-30
EP2200600B1 (en) 2011-11-09
KR20100052558A (ko) 2010-05-19
ZA201001263B (en) 2011-07-27
AR070026A1 (es) 2010-03-10
US8877814B2 (en) 2014-11-04
AU2008298015A1 (en) 2009-03-19
JP2014221767A (ja) 2014-11-27
TW200918042A (en) 2009-05-01
EP2548552B1 (en) 2015-11-18
ATE532507T1 (de) 2011-11-15
RU2011137131A (ru) 2013-03-20
JP5612473B2 (ja) 2014-10-22
AU2008298018C1 (en) 2012-08-16
ES2604945T3 (es) 2017-03-10
EP2548552A2 (en) 2013-01-23
PT2200600E (pt) 2012-02-17
JP2010539118A (ja) 2010-12-16
JP2014221766A (ja) 2014-11-27
ES2562709T3 (es) 2016-03-07
ZA201001261B (en) 2011-08-31
WO2009033649A1 (en) 2009-03-19
CA2699213A1 (en) 2009-03-19
US9468610B2 (en) 2016-10-18
JP2010539117A (ja) 2010-12-16
ZA201001264B (en) 2011-07-27
WO2009033652A1 (en) 2009-03-19
US9498450B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
ES2510565T3 (es) Envase de ajuste de dosis para neramexano y su uso en el tratamiento de un trastorno del oído interno
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
EP2444072A3 (en) Non-mucoadhesive film dosage forms
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
ECSP13012422A (es) FORMA DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 6'-FLUORO-(N-METIL- O N,N-DIMETIL)-4-FENIL-4',9'-DIHIDRO-3'H-ESPIRO[CICLOHEXAN-1,1'-PIRANO[3,4,b]INDOL]-4-AMINA PARA EL TRATAMIENTO DE DOLOR NOCICEPTIVO
PE20140872A1 (es) Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2007000945A1 (es) Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
IL196425A (en) Dosage unit for oral administration containing ibuprofen and pamotidine
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
AR062393A1 (es) Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel
ES2526359T3 (es) Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos
ECSP11010941A (es) Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis